1.Identification of an effective and safe bolus dose and lockout time for patient-controlled sedation (PCS) using dexmedetomidine in dental treatments: a randomized clinical trial
Seung-Hyun RHEE ; Young-Seok KWEON ; Dong-Ok WON ; Seong-Whan LEE ; Kwang-Suk SEO
Journal of Dental Anesthesia and Pain Medicine 2024;24(1):19-35
		                        		
		                        			 Background:
		                        			This study investigated a safe and effective bolus dose and lockout time for patient-controlled sedation (PCS) with dexmedetomidine for dental treatments. The depth of sedation, vital signs, and patient satisfaction were investigated to demonstrate safety. 
		                        		
		                        			Methods:
		                        			Thirty patients requiring dental scaling were enrolled and randomly divided into three groups based on bolus doses and lockout times: group 1 (low dose group, bolus dose 0.05 µg/kg, 1-minute lockout time), group 2 (middle dose group, 0.1 µg/kg, 1-minute), and group 3 (high dose group, 0.2 µg/kg, 3-minute) (n = 10 each). ECG, pulse, oxygen saturation, blood pressure, end-tidal CO2 , respiratory rate, and bispectral index scores (BIS) were measured and recorded. The study was conducted in two stages: the first involved sedation without dental treatment and the second included sedation with dental scaling. Patients were instructed to press the drug demand button every 10 s, and the process of falling asleep and waking up was repeated 1-5 times.In the second stage, during dental scaling, patients were instructed to press the drug demand button. Loss of responsiveness (LOR) was defined as failure to respond to auditory stimuli six times, determining sleep onset. Patient and dentist satisfaction were assessed before and after experimentation. 
		                        		
		                        			Results:
		                        			Thirty patients (22 males) participated in the study. Scaling was performed in 29 patients after excluding one who experienced dizziness during the first stage. The average number of drug administrations until first LOR was significantly lower in group 3 (2.8 times) than groups 1 and 2 (8.0 and 6.5 times, respectively). The time taken to reach the LOR showed no difference between groups. During the second stage, the average time required to reach the LOR during scaling was 583.4 seconds. The effect site concentrations (Ce) was significantly lower in group 1 than groups 2 and 3. In the participant survey on PCS, 8/10 in group 3 reported partial memory loss, whereas 17/20 in groups 1 and 2 recalled the procedure fully or partially. 
		                        		
		                        			Conclusion
		                        			PCS with dexmedetomidine can provide a rapid onset of sedation, safe vital sign management, and minimal side effects, thus facilitating smooth dental sedation. 
		                        		
		                        		
		                        		
		                        	
2.COVID-19 Vaccine-Associated Pneumonitis in the Republic of Korea:A Nationwide Multicenter Survey
Hongseok YOO ; Song Yee KIM ; Moo Suk PARK ; Sung Hwan JEONG ; Sung-Woo PARK ; Hong Lyeol LEE ; Hyun-Kyung LEE ; Sei-Hoon YANG ; Yangjin JEGAL ; Jung-Wan YOO ; Jongmin LEE ; Hyung Koo KANG ; Sun Mi CHOI ; Jimyung PARK ; Young Whan KIM ; Jin Woo SONG ; Joo Hun PARK ; Won-Il CHOI ; Hye Sook CHOI ; Chul PARK ; Jeong-Woong PARK ; Man Pyo CHUNG
Journal of Korean Medical Science 2023;38(14):e106-
		                        		
		                        			 Background:
		                        			Recent reports have suggested that pneumonitis is a rare complication following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).However, its clinical features and outcomes are not well known. The aim of this study was to identify the clinical characteristics and outcomes of patients with vaccine-associated pneumonitis following vaccination against SARS-CoV-2. 
		                        		
		                        			Methods:
		                        			In this nationwide multicenter survey study, questionnaires were distributed to pulmonary physicians in referral hospitals. They were asked to report cases of development or exacerbation of interstitial lung disease (ILD) associated with the coronavirus disease 2019 vaccine. Vaccine-associated pneumonitis was defined as new pulmonary infiltrates documented on chest computed tomography within 4 weeks of vaccination and exclusion of other possible etiologies. 
		                        		
		                        			Results:
		                        			From the survey, 49 cases of vaccine-associated pneumonitis were identified between February 27 and October 30, 2021. After multidisciplinary discussion, 46 cases were analyzed. The median age was 66 years and 28 (61%) were male. The median interval between vaccination and respiratory symptoms was 5 days. There were 20 (43%), 17 (37%), and nine (19%) patients with newly identified pneumonitis, exacerbation of pre-diagnosed ILD, and undetermined pre-existing ILD, respectively. The administered vaccines were BNT162b2 and ChAdOx1 nCov-19/AZD1222 each in 21 patients followed by mRNA-1273 in three, and Ad26.COV2.S in one patient. Except for five patients with mild disease, 41 (89%) patients were treated with corticosteroid. Significant improvement was observed in 26 (57%) patients including four patients who did not receive treatment. However, ILD aggravated in 9 (20%) patients despite treatment. Mortality was observed in eight (17%) patients. 
		                        		
		                        			Conclusion
		                        			These results suggest pneumonitis as a potentially significant safety concern for vaccines against SARS-CoV-2. Clinical awareness and patient education are necessary for early recognition and prompt management. Additional research is warranted to identify the epidemiology and characterize the pathophysiology of vaccine-associated pneumonitis. 
		                        		
		                        		
		                        		
		                        	
3.Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study
Jae Yoon JEONG ; Dae Won JUN ; Sol Ji PARK ; Joo Hyun SOHN ; Sang Gyune KIM ; Se Whan LEE ; Soung Won JEONG ; Moon Young KIM ; Won KIM ; Jae-Jun SHIM ; Hyoung Su KIM ; Ki Tae SUK ; Sang Bong AHN
The Korean Journal of Internal Medicine 2020;35(5):1074-1083
		                        		
		                        			 Background/Aims:
		                        			We aimed to assess the role of vitamin D supplementation in the response to pegylated interferon-α (PEG-IFN-α) plus ribavirin (RBV) treatment in patients with chronic hepatitis C (CHC). 
		                        		
		                        			Methods:
		                        			Our study was a multi-center, randomized controlled trial in 11 hospitals. CHC patients were randomly assigned (1:1) to two groups namely, PEGIFN-α plus RBV (control group) or PEG-IFN-α plus RBV + vitamin D (800 IU daily) (vitamin D group). The primary end-point was the rate of sustained virologic response (SVR). 
		                        		
		                        			Results:
		                        			One hundred forty eight CHC patients were randomly assigned to two groups. Seventy-one patients received the PEG-IFN-α plus RBV and 77 patients received the PEG-IFN-α plus RBV + vitamin D. A total of 105 patients completed the study (control group, 47 vs. vitamin D group, 58). Baseline characteristics were mostly similar in both the groups. There was a modest but non-significant increase in SVR in the vitamin D group compared to the control group with the intention to treat analysis (64.0% vs. 49.3 %, p = 0.071) as well as in the per protocol analysis (control group vs. vitamin D group: 74.5% vs. 84.5%, p = 0.202). Fifty-two patients (73.2%) in the control group and 63 patients (81.8%) in the vitamin D group experienced at least one adverse event. The drop-out rate due to adverseeffects was not different between both groups (control group vs. vitamin D group: 19.7% vs. 10.4%, p = 0.111). 
		                        		
		                        			Conclusions
		                        			Vitamin D supplement did not increase SVR in treatment naïve patients with CHC irrespective of genotype. 
		                        		
		                        		
		                        		
		                        	
4.Impact of Sarcopenia on Early Postoperative Complications in Early-Stage Non–Small-Cell Lung Cancer
Jiyun LEE ; Seok Whan MOON ; Jung Suk CHOI ; Kwanyong HYUN ; Young Kyu MOON ; Mi Hyoung MOON
The Korean Journal of Thoracic and Cardiovascular Surgery 2020;53(3):93-103
		                        		
		                        			 Background:
		                        			Risk assessment for pulmonary resection in patients with early-stage non– small-cell lung cancer (NSCLC) is important for minimizing postoperative morbidity. Depletion of skeletal muscle mass is closely associated with impaired nutritional status and limited physical ability. We evaluated the relationship between skeletal muscle depletion and early postoperative complications in patients with early-stage NSCLC. 
		                        		
		                        			Methods:
		                        			Patients who underwent curative lung resection between 2016 and 2018 and who were diagnosed with pathological stage I/II NSCLC were included, and their records were retrospectively analyzed. The psoas volume index (PVI, cm3/m3) was calculated based on computed tomography images from routine preoperative positron emission tomography- computed tomography. Early postoperative complications, defined as those occurring within 90 days of surgery, were compared between the lowest sex-specific quartile for PVI and the remaining quartiles. 
		                        		
		                        			Results:
		                        			A strong correlation was found between the volume and the cross-sectional area of the psoas muscle (R2=0.816). The overall rate of complications was 57.6% among patients with a low PVI and 32.8% among those with a normal-to-high PVI. The most common complication was prolonged air leak (low PVI, 16.9%; normal-to-high PVI, 9.6%), followed by pneumonia (low PVI, 13.6%; normal-to-high PVI, 7.9%) and recurrent pleural effusion (low PVI, 11.9%; normal-to-high PVI, 6.8%). The predictors of overall complications were low PVI (odds ratio [OR], 2.18; 95% confidence interval [CI], 1.07–4.09; p=0.03), low hemoglobin level (OR, 0.686; 95% CI, 0.54–0.87; p=0.002), and smoking history (OR, 3.93; 95% CI, 2.03–7.58; p<0.001). 
		                        		
		                        			Conclusion
		                        			Low PVI was associated with a higher rate of early postoperative complications in patients with early-stage NSCLC. 
		                        		
		                        		
		                        		
		                        	
5.Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 2. Idiopathic Pulmonary Fibrosis
Sang Hoon LEE ; Yoomi YEO ; Tae Hyung KIM ; Hong Lyeol LEE ; Jin Hwa LEE ; Yong Bum PARK ; Jong Sun PARK ; Yee Hyung KIM ; Jin Woo SONG ; Byung Woo JHUN ; Hyun Jung KIM ; Jinkyeong PARK ; Soo Taek UH ; Young Whan KIM ; Dong Soon KIM ; Moo Suk PARK ;
Tuberculosis and Respiratory Diseases 2019;82(2):102-117
		                        		
		                        			
		                        			 Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial pneumonia, which presents with a progressive worsening dyspnea, and thus a poor outcome. The members of the Korean Academy of Tuberculosis and Respiratory Diseases as well as the participating members of the Korea Interstitial Lung Disease Study Group drafted this clinical practice guideline for IPF management. This guideline includes a wide range of topics, including the epidemiology, pathogenesis, risk factors, clinical features, diagnosis, treatment, prognosis, and acute exacerbation of IPF in Korea. Additionally, we suggested the PICO for the use of pirfenidone and nintendanib and for lung transplantation for the treatment of patients with IPF through a systemic literature review using experts' help in conducting a meta-analysis. We recommend this guideline to physicians, other health care professionals, and government personnel in Korea, to facilitate the treatment of patients with IPF. 
		                        		
		                        		
		                        		
		                        	
6.Preliminary results of entire pleural intensity-modulated radiotherapy in a neoadjuvant setting for resectable malignant mesothelioma
Ji Hyun HONG ; Hyo Chun LEE ; Kyu Hye CHOI ; Seok Whan MOON ; Kyung Soo KIM ; Suk Hee HONG ; Ju Young HONG ; Yeon Sil KIM ;
Radiation Oncology Journal 2019;37(2):101-109
		                        		
		                        			
		                        			PURPOSE: The purpose of this study is to evaluate the safety and efficacy of the multimodality treatment with neoadjuvant intensity-modulated radiotherapy (IMRT) for resectable clinical T1-3N0-1M0 malignant pleural mesothelioma (MPM). MATERIALS AND METHODS: A total of eleven patients who received neoadjuvant chemotherapy and radiotherapy between March 2016 and June 2018 were reviewed. Patients received 25 Gy in 5 fractions to entire ipsilateral hemithorax with helical tomotherapy. RESULTS: All of patients were men with a median age of 56 years. Epithelioid subtype was found in 10 patients. All patients received neoadjuvant chemotherapy with pemetrexed-cisplatin regimen. Ten patients (90.9%) completed 25 Gy/5 fractions and one (9.0%) completed 20 Gy/4 fractions of radiotherapy. IMRT was well tolerated with only one acute grade 3 radiation pneumonitis. Surgery was performed 1 week (median, 8 days; range, 1 to 15 days) after completing IMRT. Extrapleural pneumonectomy was performed in 4 patients (36.3%), extended pleurectomy/decortication in 2 (18.2%) and pleurectomy/decortications in 5 (63.6%). There was no grade 3+ surgical complication except two deaths after EPP in 1 month. Based on operative findings and pathologic staging, adjuvant chemotherapy was delivered in 7 patients (63.6%), and 2 (18.2%) were decided to add adjuvant radiotherapy. After a median follow-up of 14.6 months (range, 2.8 to 30 months), there were 3 local recurrence (33.3%) and 1 distant metastasis (11.1%). CONCLUSION: Neoadjuvant entire pleural IMRT can be delivered with a favorable radiation complication. An optimal strategy has to be made in resectable MPM patients who would benefit from neoadjuvant radiation and surgery. Further studies are needed to look at long-term outcomes.
		                        		
		                        		
		                        		
		                        			Chemotherapy, Adjuvant
		                        			;
		                        		
		                        			Combined Modality Therapy
		                        			;
		                        		
		                        			Drug Therapy
		                        			;
		                        		
		                        			Follow-Up Studies
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Mesothelioma
		                        			;
		                        		
		                        			Neoadjuvant Therapy
		                        			;
		                        		
		                        			Neoplasm Metastasis
		                        			;
		                        		
		                        			Pneumonectomy
		                        			;
		                        		
		                        			Radiation Pneumonitis
		                        			;
		                        		
		                        			Radiotherapy
		                        			;
		                        		
		                        			Radiotherapy, Adjuvant
		                        			;
		                        		
		                        			Radiotherapy, Intensity-Modulated
		                        			;
		                        		
		                        			Recurrence
		                        			
		                        		
		                        	
7.Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 2. Idiopathic Pulmonary Fibrosis
Sang Hoon LEE ; Yoomi YEO ; Tae Hyung KIM ; Hong Lyeol LEE ; Jin Hwa LEE ; Yong Bum PARK ; Jong Sun PARK ; Yee Hyung KIM ; Jin Woo SONG ; Byung Woo JHUN ; Hyun Jung KIM ; Jinkyeong PARK ; Soo Taek UH ; Young Whan KIM ; Dong Soon KIM ; Moo Suk PARK ;
Tuberculosis and Respiratory Diseases 2019;82(2):102-117
		                        		
		                        			
		                        			Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial pneumonia, which presents with a progressive worsening dyspnea, and thus a poor outcome. The members of the Korean Academy of Tuberculosis and Respiratory Diseases as well as the participating members of the Korea Interstitial Lung Disease Study Group drafted this clinical practice guideline for IPF management. This guideline includes a wide range of topics, including the epidemiology, pathogenesis, risk factors, clinical features, diagnosis, treatment, prognosis, and acute exacerbation of IPF in Korea. Additionally, we suggested the PICO for the use of pirfenidone and nintendanib and for lung transplantation for the treatment of patients with IPF through a systemic literature review using experts' help in conducting a meta-analysis. We recommend this guideline to physicians, other health care professionals, and government personnel in Korea, to facilitate the treatment of patients with IPF.
		                        		
		                        		
		                        		
		                        			Delivery of Health Care
		                        			;
		                        		
		                        			Diagnosis
		                        			;
		                        		
		                        			Disease Management
		                        			;
		                        		
		                        			Dyspnea
		                        			;
		                        		
		                        			Epidemiology
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Idiopathic Pulmonary Fibrosis
		                        			;
		                        		
		                        			Korea
		                        			;
		                        		
		                        			Lung Diseases, Interstitial
		                        			;
		                        		
		                        			Lung Transplantation
		                        			;
		                        		
		                        			Prognosis
		                        			;
		                        		
		                        			Risk Factors
		                        			;
		                        		
		                        			Tuberculosis
		                        			
		                        		
		                        	
8.A 2-Week Steroid Trial for Differentiating Isolated IgG4-Related Sclerosing Cholangitis from Cholangiocarcinoma.
Bho Hyeon LEE ; Sung Hoon MOON ; Kyueng Whan MIN ; Ji Won PARK ; Hyun LIM ; Sung Eun KIM ; Ho Suk KANG ; Jong Hyeok KIM
Korean Journal of Pancreas and Biliary Tract 2018;23(3):127-133
		                        		
		                        			
		                        			Immunoglobulin G4-related sclerosing cholangitis (IgG4-SC) is rare disease which is steroid-responsive and often associated with IgG4 related systemic disease such as autoimmune pancreatitis. It is characterized by increased serum IgG4 and IgG4-positive lymphoplasmacytic infiltration in bile ducts. It is often difficult to distinguish IgG4-SC to hilar cholangiocarcinoma if it manifests as an isolated bile duct. We report a case of 79-year-old woman with IgG4-SC which was difficult to distinguish hilar cholangiocarcinoma due to similar clinical and radiologic findings, showing good therapeutic effect after a 2-week steroid trial.
		                        		
		                        		
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Bile Ducts
		                        			;
		                        		
		                        			Cholangiocarcinoma*
		                        			;
		                        		
		                        			Cholangitis, Sclerosing*
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Immunoglobulin G
		                        			;
		                        		
		                        			Immunoglobulins
		                        			;
		                        		
		                        			Klatskin Tumor
		                        			;
		                        		
		                        			Pancreatitis
		                        			;
		                        		
		                        			Rare Diseases
		                        			
		                        		
		                        	
9.Comparison of the anesthetic effects of 2,2,2-tribromoethanol on ICR mice derived from three different sources.
Mi Ree LEE ; Hye Rin SUH ; Myeong Whan KIM ; Joon Young CHO ; Hyun Keun SONG ; Young Suk JUNG ; Dae Youn HWANG ; Kil Soo KIM
Laboratory Animal Research 2018;34(4):270-278
		                        		
		                        			
		                        			This study was conducted to compare the anesthetic effects of 2,2,2-tribromoethanol (TBE, Avertin®) in ICR mice obtained from three different sources. TBE (2.5%) was intraperitoneally injected at three doses: high-dose group (500 mg/kg), intermediate-dose group (250 mg/kg), and low-dose group (125 mg/kg). Anesthesia time, recovery time, end-tidal peak CO2 (ETCO₂), mean arterial blood pressure, heart rate, oxygen saturation (SpO₂), body temperature, pH, PCO₂, and PO₂ of the arterial blood were measured. Stable anesthesia was induced by all doses of TBE and the anesthesia time was maintained exhibited dose dependency. No significant differences in anesthetic duration were found among the three different strains. However, the anesthesia time was longer in female than in male mice, and the duration of anesthesia was significantly longer in female than in male mice in the high-dose group. The recovery time was significantly longer for female than male mice in the intermediate- and high-dose groups. In the ICR strains tested, there were no significant differences in the mean arterial blood pressure, SPO₂, arterial blood PCO₂, and PO₂, which decreased after TBE anesthesia, or in heart rate and ETCO₂, which increased after TBE anesthesia. In addition, body temperature, blood biochemical markers, and histopathological changes of the liver, kidney, and lung were not significantly changed by TBE anesthesia. These results suggested that ICR mice from different sources exhibited similar overall responses to a single exposure to TBE anesthesia. In conclusion, TBE is a useful drug that can induce similar anesthetic effects in three different strains of ICR mice.
		                        		
		                        		
		                        		
		                        			Anesthesia
		                        			;
		                        		
		                        			Anesthetics*
		                        			;
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Arterial Pressure
		                        			;
		                        		
		                        			Biomarkers
		                        			;
		                        		
		                        			Body Temperature
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Heart Rate
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Hydrogen-Ion Concentration
		                        			;
		                        		
		                        			Kidney
		                        			;
		                        		
		                        			Liver
		                        			;
		                        		
		                        			Lung
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Mice
		                        			;
		                        		
		                        			Mice, Inbred ICR*
		                        			;
		                        		
		                        			Oxygen
		                        			;
		                        		
		                        			Sex Characteristics
		                        			
		                        		
		                        	
10.Ulnar Nerve Injury Caused by the Incomplete Insertion of a Screw Head after Internal Fixation with Dual Locking Plates in AO/OTA Type C2 Distal Humerus Fractures.
Jae Hyuk SHIN ; Whan Jin KWON ; Yoon Suk HYUN
Clinics in Shoulder and Elbow 2017;20(4):236-239
		                        		
		                        			
		                        			After dual plating with a locking compression plate for comminuted intraarticular fractures of the distal humerus, the incidence of ulnar nerve injury after surgery has been reported to be up to 38%. This can be reduced by an anterior transposition of the ulnar nerve but some surgeons believe that extensive handling of the nerve with transposition can increase the risk of an ulnar nerve dysfunction. This paper reports ulnar nerve injuries caused by the incomplete insertion of a screw head in dual plating without an anterior ulnar nerve transposition for AO/OTA type C2 distal humerus fractures. When an anatomical locking plate is applied to a distal humeral fracture, locking screws around the ulnar nerve should be inserted fully without protrusion of the screw because an incompletely inserted screw can cause irritation or injury to the ulnar nerve because the screw head in the locking system usually has a slightly sharp edge because screw head has threads. If the change in insertion angle and resulting protruded head of the screw are unavoidable for firm fixation of fracture, the anterior transposition of the ulnar nerve is recommended over a soft tissue shield.
		                        		
		                        		
		                        		
		                        			Head*
		                        			;
		                        		
		                        			Humeral Fractures
		                        			;
		                        		
		                        			Humerus*
		                        			;
		                        		
		                        			Incidence
		                        			;
		                        		
		                        			Intra-Articular Fractures
		                        			;
		                        		
		                        			Surgeons
		                        			;
		                        		
		                        			Ulnar Nerve*
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail